Detalhe da pesquisa
1.
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
J Clin Oncol
; 36(16): 1556-1563, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29664714